Clinical

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.

An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.

Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.

No trial has shown a significant FEV1 benefit, yet FEV1 may be the wrong yardstick for emphysema. CT densitometry and real-world comparisons support augmentation, while testing and liver coordination remain unmet needs.

Three-year survival data gives patients something rare in extensive-stage disease: a concrete number to hold onto. Nearly one in five patients alive at three years reframes what a durable tail of the curve can mean.

Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.

Reluctance toward injectable therapy is diminishing, but it persists. Dosing convenience and an honest conversation about the cumulative harm of steroid bursts can change a patient's decision.

Topical JAK inhibitors, phototherapy, and combination strategies now anchor first-line vitiligo treatment. Drs. Desai and Hamzavi compare their approaches and the evidence shaping how aggressively they treat localized disease.

Each exacerbation erodes lung function, and reduced lung function invites the next exacerbation. The panel explains why biologics are shifting from last resort to earlier intervention.

Vitiligo care rarely stays within dermatology alone. The panel discusses when to loop in primary care, endocrinology, psychology, and patient support networks to address the disease's full burden.

Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.

Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).

HS is a systemic disease with significant comorbidity, which complicates care. Dr. Lev-Tov argues that published guidelines and clear referral pathways make this burden manageable for dermatologists and other clinicians.

Four DOACs, four dosing schemes, and low adherence complicate stroke prevention. Dr. Barnes reviews dose-reduction criteria and the discontinuation rates that clinicians must address.

Earlier treatment appears to improve the likelihood of remission in HS. Dr. Lev-Tov challenges clinicians to rethink what counts as moderate disease and to consider advanced therapies sooner.

The move from warfarin to DOACs reduced monitoring burden and expanded treatment, but it also reduced patient contact with the health care team. Dr. Barnes weighs the trade-offs.

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Disability in MS accrues through two distinct biological engines. Recognizing relapse-independent progression changes how clinicians assess patients and how they build trust with those who feel worse despite stable MRI.

Efficacy sets the starting point, but performance status, comorbidities, patient priorities, and distinct adverse event patterns determine which first-line regimen a patient actually receives.

Behind every case of bronchiectasis is a self-perpetuating cycle of cough, breathlessness, and infection that leaves many patients unable to return to their prior baseline health.

Bronchiectasis pathophysiology looks less linear and more dynamic than once believed, and its true prevalence appears far higher than commonly assumed across the adult population.

MS prevalence continues to rise and the demographic profile is broader than long assumed. The panel identifies progressive biology as the largest remaining unmet need in the disease.

A rare EGFR subtype demands comprehensive molecular testing at diagnosis, and the first-line standard has shifted from chemotherapy alone to a targeted combination with survival benefit.